Ga-68-BPAMD: PET-imaging of bone metastases with a generator based positron emitter

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F12%3A10124831" target="_blank" >RIV/00216208:11310/12:10124831 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.nucmedbio.2012.04.007" target="_blank" >http://dx.doi.org/10.1016/j.nucmedbio.2012.04.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.nucmedbio.2012.04.007" target="_blank" >10.1016/j.nucmedbio.2012.04.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Ga-68-BPAMD: PET-imaging of bone metastases with a generator based positron emitter

Popis výsledku v původním jazyce

Purpose: Bone metastases are a serious aggravation for patients suffering from cancer. Therefore, early recognition of bone metastases is of great interest for further treatment of patients. Bisphosphonates are widely used for scintigraphy of bone lesions with Tc-99m. Using the Ge-68/Ga-68 generator together with a macroyclic bisphosphonate a comparable PET-tracer comes into focus. Procedures: The bisphosphonate DOTA-conjugated ligand BPAMD was labelled with Ga-68. [Ga-68]BPAMD was evaluated in vitro concerning binding to hydroxyapatite and stability. The tracer's in vivo accumulation was determined on healthy rats and bone metastases bearing animals by mu-PET. Results: BPAMD was labelled efficiently with 68Ga after 10 min at 100 degrees C. [Ga-68]BPAMD allowed high in vitro stability within 3 h and high binding to hydroxyapatite. Consequently, mu-PET experiments revealed high accumulation of [Ga-68]BPAMD in regions of pronounced remodelling activity like bone metastases. Conclusions:

Název v anglickém jazyce

Ga-68-BPAMD: PET-imaging of bone metastases with a generator based positron emitter

Popis výsledku anglicky

Purpose: Bone metastases are a serious aggravation for patients suffering from cancer. Therefore, early recognition of bone metastases is of great interest for further treatment of patients. Bisphosphonates are widely used for scintigraphy of bone lesions with Tc-99m. Using the Ge-68/Ga-68 generator together with a macroyclic bisphosphonate a comparable PET-tracer comes into focus. Procedures: The bisphosphonate DOTA-conjugated ligand BPAMD was labelled with Ga-68. [Ga-68]BPAMD was evaluated in vitro concerning binding to hydroxyapatite and stability. The tracer's in vivo accumulation was determined on healthy rats and bone metastases bearing animals by mu-PET. Results: BPAMD was labelled efficiently with 68Ga after 10 min at 100 degrees C. [Ga-68]BPAMD allowed high in vitro stability within 3 h and high binding to hydroxyapatite. Consequently, mu-PET experiments revealed high accumulation of [Ga-68]BPAMD in regions of pronounced remodelling activity like bone metastases. Conclusions:

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CA - Anorganická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/OC%20179" target="_blank" >OC 179: Molekulární zobrazování založené na systémech obsahujících kovy.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nuclear Medicine and Biology

ISSN

0969-8051

e-ISSN

—

Svazek periodika

39

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

993-999

Kód UT WoS článku

000309033800016

EID výsledku v databázi Scopus

—